Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clearmind Medicine Inc CMND

Healthcare
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or... see more

Recent & Breaking News (NDAQ:CMND)

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine's Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

GlobeNewswire January 25, 2023

Clearmind (CSE:CMND) successfully completes two R&D projects

Shoran Devi January 19, 2023

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem's Tech Transfer Company, Yissum

GlobeNewswire January 19, 2023

Clearmind (CSE:CMND) adds results for a pre-clinical study for cocaine addiction treatment

Brieanna McCutcheon  January 17, 2023

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

GlobeNewswire January 17, 2023

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

GlobeNewswire January 10, 2023

Clearmind Medicine (CSE:CMND) demonstrates efficacy of psychedelic-derived obesity treatment in pre-clinical trial

Azuka Onwuka January 5, 2023

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

GlobeNewswire January 5, 2023

Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com

Accesswire January 4, 2023

Clearmind Medicine Announces Shareholders Meeting Results

GlobeNewswire December 29, 2022

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

GlobeNewswire December 28, 2022

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani

Accesswire December 22, 2022

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

GlobeNewswire December 21, 2022

Israeli Based Biotech Company Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

GlobeNewswire December 15, 2022

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

GlobeNewswire December 13, 2022

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute

GlobeNewswire December 9, 2022

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

GlobeNewswire November 23, 2022

Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)

Accesswire November 17, 2022

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

GlobeNewswire November 17, 2022